Medpage Today on MSN2d
Midlife Choices May Offset Genetic Risk for Dementia, Stroke, Late-Life DepressionFor all three outcomes -- dementia, stroke, and late-life depression -- the median follow-up was 12.5 years. During follow-up ...
MedPage Today on MSN2d
Slow Start for AI-Assisted Screening for Diabetic Retinopathy Despite PromiseParikh reported receiving consulting fees from Anthem Blue Cross Blue Shield, Regeneron, and Apellis Pharmaceuticals; serving ...
As with many other companies Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) makes use of debt. But should shareholders be worried about its use of debt? Generally speaking, debt only becomes a real ...
Patients with moderate to severe HS experienced sustained symptomatic and quality-of-life improvements with the monoclonal ...
Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...
Medpage Today on MSN3d
Watch for Psoriasis After Cancer Immunotherapy, Study SaysPD-1 and PD-L1 immune checkpoint inhibitors (ICIs) for treating advanced cancer were associated with an increased risk of new ...
GlobalData on MSN3d
EMA approves Sanofi/Regeneron’s Dupixent for young EoE patientsThe European Medicines Agency (EMA) approved Sanofi/Regeneron’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) ...
Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $1,000 from $1,150 and keeps an Outperform rating on the shares. With ...
Regeneron (REGN) and Sanofi (SNY) announced that the European Commission, or EC, has approved Dupixent to treat eosinophilic esophagitis, or ...
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an ...
Shares of Regeneron Pharmaceuticals Inc. REGN inched 0.07% higher to $829.43 Tuesday, on what proved to be an all-around ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback